Welcome to our dedicated page for INVESTMENT MANAGERS SER TR II SEC filings (Ticker: SNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SNPX SEC filings page on Stock Titan provides access to the historical regulatory record of Synaptogenix, Inc., which later changed its name to TAO Synergies Inc. and its Nasdaq ticker to TAOX. These documents include current reports, proxy statements, and registration-related materials that show both the company’s biopharmaceutical activities and its subsequent shift to a TAO-focused digital asset treasury strategy.
Among the key filings is a Form 8-K dated June 27, 2025, in which the company reports filing a certificate of amendment to change its name to TAO Synergies Inc. and explains that its common stock would cease trading under the SNPX symbol and begin trading under TAOX on the Nasdaq Capital Market. The filing notes that the CUSIP for the common stock did not change and clarifies that the name change did not alter the rights associated with the shares.
Another Form 8-K dated June 24, 2025 discusses the company’s initial purchase of the TAO token as part of its cryptocurrency treasury strategy and the engagement of BitGo to provide qualified custody, staking, and trading services. This filing describes how the company planned to generate yield by staking TAO from qualified custody and states that the initial acquisition was funded from cash reserves.
A definitive proxy statement on Schedule 14A dated July 7, 2025, filed under the TAO Synergies Inc. name but referencing the former Synaptogenix identity, outlines matters to be voted on at a special meeting of stockholders. These include authorization of share issuances related to Series D preferred stock and warrants, amendments to the company’s equity incentive plan (including renaming it as the TAO Synergies Inc. 2020 Equity Incentive Plan), and potential adjournment of the meeting if additional proxies are needed.
Through Stock Titan, users can view these and other historical SNPX filings and take advantage of AI-powered summaries that highlight the main points of complex documents. The platform surfaces information from current reports, proxy materials, and other SEC submissions so that investors can more quickly understand name changes, financing structures, equity plans, and strategic shifts, and then follow the company’s ongoing disclosures under its current TAOX ticker.
TAO Synergies (formerly Synaptogenix) has announced a special virtual stockholder meeting on August 6, 2025 to vote on three key proposals:
- Authorization to issue common stock underlying convertible preferred stock and warrants from a June 9, 2025 Securities Purchase Agreement, including 5,500 shares of Series D preferred stock convertible into 1,833,333 common shares at $3.00 per share, plus corresponding warrants
- Approval of amendments to the 2020 Equity Incentive Plan to increase available shares by 2 million and rename it to "TAO Synergies Inc. 2020 Equity Incentive Plan"
- Approval of a consulting agreement with James Altucher and Z-List Media, granting warrants for 1.2 million common shares at exercise prices ranging from $4.00 to $12.00 per share for crypto portfolio management and strategic services
The proposals require stockholder approval to comply with Nasdaq Listing Rules 5635(c) and 5635(d). The board recommends approval of all proposals. Record date for voting eligibility is June 9, 2025.
Synaptogenix (Nasdaq: SNPX) filed an 8-K reporting two material items: a leadership change and a corporate rebranding.
- CEO resignation: Dr. Alan J. Tuchman stepped down as Chief Executive Officer effective June 8 2025, but remains on the board and becomes Chief Medical Officer; his base salary is reduced to $7,500 per month.
- Name & ticker change: On June 26 2025 the company changed its name to TAO Synergies Inc. via a Delaware certificate of amendment. The Nasdaq symbol will switch from SNPX to TAOX on July 1 2025. No shareholder vote was required under DGCL §242.
The filing also corrects a prior 8-K that mistakenly said Dr. Tuchman resigned from the board; he continues as a director. Exhibits 3.1 and 99.1 provide the amendment and related press release.